Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2006 Sep 29;24(40-41):6437-45. Epub 2006 Jun 13.

Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children.

Author information

  • 1Department of Communicable Disease Surveillance and Control, Directorate General of Health Affairs, Ministry of Health, Muscat, Sultanate of Oman.


As part of the national plan for elimination of rubella and congenital rubella syndrome (CRS), Oman established a national registry of CRS cases. As of May 2005, the registry included 43 surviving CRS cases, with a mean age of 11.9 years. Clinical examinations found that 84% had ocular defects, 84% had auditory/speech defects, 70% had neurological manifestations, and 42% had cardiac defects. Lifetime medical, special education, and rehabilitation costs were assessed. Using a discount rate of 3%, the average direct lifetime cost per surviving CRS patient was estimated at 18,644 US dollars. When including predicted lost productivity due to CRS, the average discounted direct and indirect lifetime costs per surviving CRS patient amounted to 98,734 US dollars.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk